07.03.26 -- Drug Discovery Online Best Of June

Linda Griffith, MIT biological engineering professor and pioneer in tissue engineering, and Don Ingber, founding director of the Wyss Institute and leading architect of organ‑on‑chip systems, dissect the role of hype in new approach methodologies—where it drives adoption, and where it risks eroding trust.

The EU is establishing a credible and scalable NAM ecosystem, but challenges still need to be overcome before life sciences professionals and patients can reap the benefits.

In a live audience poll, 46% of respondents cited validation and trust as the biggest barriers to broader organ‑on‑chip adoption. The result suggests the technology itself is no longer the main hurdle; instead, confidence in reproducibility, benchmarking, and fit‑for‑purpose use will determine how quickly these models are integrated into drug discovery decision‑making.

Gain insight into ELISA fundamentals, data interpretation, and workflow optimization, supported by real lab examples and step‑by‑step guidance to help researchers improve accuracy and reduce variability.

Lipid nanoparticles enable precise, non-viral gene editing in T cells to achieve high HDR efficiency and viability in scalable workflows. Explore how this approach overcomes viral vector limitations.

Standardized analytical data is key to improving data quality, reuse, and AI readiness. Discover the challenges of fragmented formats and gain practical guidance on building future-proof foundations.